IN BRIEF: N4 Pharma teams up with University of Strathclyde facility

Related news

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology - Announces partnership with Glasgow-based University of Strathclyde’s CMAC National Facility, aimed at accelerating development and broadening therapeutic applications. The collaboration combines N4 Pharma’s Nuvec delivery platform with CMAc’s expertise.

CMAC Industry Director Massimo Bresciani says: ‘This project demonstrates the strength of industry-academic partnerships in accelerating medicines manufacturing. By combining N4 Pharma’s innovative delivery platform with CMAC’s technical expertise, we aim to unlock new possibilities in RNA therapeutics.’

Current stock price: 0.71 pence each, closed 2.7% lower on Tuesday in London

12-month change: up 28%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Contract wins

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.